Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 3

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 1(2)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05283902Completed

Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly

Role: collaborator

NCT05225285Phase 3Unknown

Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents

Role: collaborator

NCT05133609Phase 1Unknown

COVID-19 VACCINE SAFETY AND EFFECTIVENESS

Role: collaborator

NCT05059106Phase 2Unknown

EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19

Role: collaborator

NCT02476773Phase 1Completed

Study of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel in Brazilian Adults

Role: collaborator

NCT01896362Completed

The Healthcare Professionals and the Leishmaniasis

Role: lead

All 6 trials loaded